Page last updated: 2024-10-28

hypericin and Nasopharyngeal Carcinoma

hypericin has been researched along with Nasopharyngeal Carcinoma in 1 studies

Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.

Research Excerpts

ExcerptRelevanceReference
"In order to explore the combined effects of gene therapy and hypericin (Hy) on tumor cells, hypoxia-inducible factor 1 alpha (HIF-1α) small interfering ribonucleic acid (siRNA) was transfected into the hypoxic human nasopharyngeal carcinoma (CNE2) cells using Hy-encapsulated nanocomplexes (Hy-HPP NPs) as a carrier which would achieve dual targeting to the tumor necrosis area."3.83Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles. ( Li, Y; Ouahab, A; Shen, Y; Wang, B; Zhang, J, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, Y1
Zhang, J1
Wang, B1
Shen, Y1
Ouahab, A1

Other Studies

1 other study available for hypericin and Nasopharyngeal Carcinoma

ArticleYear
Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
    Drug development and industrial pharmacy, 2016, Volume: 42, Issue:5

    Topics: Anthracenes; Carcinoma; Cell Line, Tumor; Humans; Hyaluronic Acid; Hypoxia-Inducible Factor 1, alpha

2016